阿霉素的药物动力学与临床观察  

Pharmacokinetic study and clinical observation of doxo-rubicin

作　　者：陆婉琴[1] 徐静芳[1] 高浩荣[2] 孙璐璐[3] 孙曾一[2] 

机构地区：[1]上海医科大学肿瘤医院抗癌药临床药理室,上海200032 [2]上海医科大学肿瘤医院化疗科,上海200032 [3]上海医科大学肿瘤医院心电图室,上海200032

出　　处：《新药与临床》1991年第1期51-53,共3页

摘　　要：本文报告应用荧光分光光度法测定6例肿瘤患者在接受国产阿霉素(50mg/次)后血药浓度的结果,血药浓度峰值在0.75-1.97μg/mL之间,肿瘤肿块缩小或不增大。未见心脏毒性。药物动力学主要参数:T_(1/2α)(分布相)=1.3h,T_(1/2β)(消除相)=34h,K_(el)=0.78h~_(-1),K_(12)=3.43h^(-1),K_(21)=0.11h^(-1)。表明国产阿霉素具有国外同类产品的特点。Doxorubicin (domestic product) 50 mg were injected iv to 6 patients (3M, 3F; age 35±SD 20 yr) with malignant tumors. The plasma concentration of the drug was determined by spectrofluorometry(βex = 472 nm,βem =590 nm). The pharmacokinetic parameters were calculated: T=1.3h, T=34 h, Kel = 0.78h-1, K12 = 3.43-1, K21 = 0.11h-1; peak concentration: 1.3±0.5 μ,g/mL which was within the therapeutic range. The data suggest that the domestic doxorubicin may be used to treat malignant tumors as well.

关 键 词：阿霉素 药物动力学 荧光光谱测定法 

分 类 号：R978.19[医药卫生—药品]